Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Precision Medicine Modeling Helps Advance Colorectal Cancer Care

August 30th 2015

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

Cancer Immunotherapy Meets Precision Medicine in Biomarker Study

August 29th 2015

Mismatch repair deficiency may serve as an immuno-oncology biomarker and may illustrate the clinical utility of analyzing the number of mutations per tumor.

Dr. Gitlitz on EGFR Exon 20 Insertion Mutations in Lung Cancer

August 28th 2015

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

Rapidly Evolving Lung Cancer Treatment Landscape

August 27th 2015

Checkpoint Inhibitors for Malignant Pleural Mesothelioma

August 27th 2015

Immunotherapy AEs and Treatment Duration in NSCLC

August 27th 2015

Checkpoint Inhibitors in Small-Cell Lung Cancer

August 27th 2015

Frontline Immunotherapy Combinations for NSCLC

August 27th 2015

Checkpoint Inhibitor Biomarkers for Lung Cancer

August 27th 2015

Emerging Landscape of Immunotherapy in NSCLC

August 27th 2015

Bevacizumab in EGFR-Mutant NSCLC

August 27th 2015

Bevacizumab in Nonsquamous NSCLC

August 27th 2015

Bevacizumab in Malignant Pleural Mesothelioma

August 27th 2015

New Therapies for Squamous NSCLC

August 27th 2015

Cabozantinib in RET-Rearranged NSCLC

August 27th 2015

Dual Targeting of BRAF and MEK in NSCLC

August 27th 2015

CNS Activity With Next-Generation ALK Inhibitors

August 27th 2015

Overcoming EGFR Inhibitor Resistance in Non-T790M-Positive NSCLC

August 27th 2015

Impressive Findings for Next-Generation EGFR Inhibitors

August 27th 2015

Upfront EGFR-Targeted Therapy for NSCLC

August 27th 2015